Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant in ER+/HER2- Breast Cancer with ctDNA Relapse
NCT05512364Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2023
- Primary completion
- Nov 2032
- Modality
- Molecular Glues
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of elacestrant in breast cancer (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Distant metastasis free survival at 6.25 years. Started Dec 2023; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05512364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512364.